These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 39207123)

  • 1. Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBC.
    Karpińska K; Mehlich D; Sabbasani VR; Łomiak M; Torres-Ayuso P; Wróbel K; Truong VN; Serwa R; Swenson RE; Brognard J; Marusiak AA
    J Med Chem; 2024 Sep; 67(17):15012-15028. PubMed ID: 39207123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease activated receptor-1 regulates mixed lineage kinase-3 to drive triple-negative breast cancer tumorigenesis.
    Srivastava P; Jha S; Singh SK; Vyas H; Sethupathi P; Nair RS; Ramachandran K; Rana B; Kumar S; Rana A
    Cancer Lett; 2024 Oct; 603():217200. PubMed ID: 39222677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
    Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY
    Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of a novel PAK1 degrader for the treatment of triple negative breast cancer.
    Du Y; Chen X; Chen W; Chen G; Cheng X; Wang H; Guo L; Li C; Yao D
    Bioorg Med Chem; 2024 Oct; 112():117896. PubMed ID: 39214014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase.
    Wang H; Li C; Liu X; Ma M
    Bioorg Med Chem; 2022 May; 61():116707. PubMed ID: 35344835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2.
    Velez J; Dale B; Park KS; Kaniskan HÜ; Yu X; Jin J
    Eur J Med Chem; 2024 Mar; 267():116154. PubMed ID: 38295690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer.
    Adams CM; Mitra R; Xiao Y; Michener P; Palazzo J; Chao A; Gour J; Cassel J; Salvino JM; Eischen CM
    Cancer Discov; 2023 May; 13(5):1210-1229. PubMed ID: 36734633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.
    Zou ZF; Yang L; Nie HJ; Gao J; Lei SM; Lai Y; Zhang F; Wagner E; Yu HJ; Chen XH; Xu ZA
    Acta Pharmacol Sin; 2024 Aug; 45(8):1740-1751. PubMed ID: 38609561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
    Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
    J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2.
    Dale B; Anderson C; Park KS; Kaniskan HÜ; Ma A; Shen Y; Zhang C; Xie L; Chen X; Yu X; Jin J
    ACS Pharmacol Transl Sci; 2022 Jul; 5(7):491-507. PubMed ID: 35837138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent small molecule PROTACs targeting mutant EGFR.
    Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TrkA expression directs the anti-neoplastic activity of MLK3 inhibitors in triple-negative breast cancer.
    Nair RS; Kumar S; Das S; Singh SK; Srivastava P; Sondarva G; Rao A; Sinha SC; Xiong R; Bloem L; Hoskins K; Thatcher GRJ; Rana B; Rana A
    Oncogene; 2023 Mar; 42(14):1132-1143. PubMed ID: 36813855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1).
    Yang J; Wu Y; Zhu Q; Qu X; Ou H; Liu H; Wei Y; Ge D; Lu C; Jiang B; Song X
    Bioorg Chem; 2024 Sep; 150():107590. PubMed ID: 38955003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
    Zhao Q; Ren C; Liu L; Chen J; Shao Y; Sun N; Sun R; Kong Y; Ding X; Zhang X; Xu Y; Yang B; Yin Q; Yang X; Jiang B
    J Med Chem; 2019 Oct; 62(20):9281-9298. PubMed ID: 31539241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
    Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring Degradation of Intrinsically Disordered Protein Yes-Associated Protein Induced by Proteolysis TArgeting Chimeras.
    Zhou C; Sun C; Huang M; Tang X; Pi L; Li C
    J Med Chem; 2024 Sep; 67(17):15168-15198. PubMed ID: 39189384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer.
    Zhao R; Fu L; Yuan Z; Liu Y; Zhang K; Chen Y; Wang L; Sun D; Chen L; Liu B; Zhang L
    Eur J Med Chem; 2021 Jan; 210():113088. PubMed ID: 33316691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies.
    Yu X; Xu J; Shen Y; Cahuzac KM; Park KS; Dale B; Liu J; Parsons RE; Jin J
    J Med Chem; 2022 Feb; 65(4):3644-3666. PubMed ID: 35119851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
    Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
    FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.